Objective: Therapeutic decision-making in metastatic renal cell carcinoma (MRCC) is based on conventional radiological evaluation. Fluorodeoxyglucose positron emission tomography (FDG-PET) scans may modify this strategy. Methods: Patients with MRCC for whom a therapeutic decision had been made underwent an FDG-PET scan in order to complete the standard radiological evaluation. Results: Twenty-four patients and 26 FDG-PET scans were eligible. In 18 patients, metastatic disease was evaluable on the computed tomography (CT) scan; the FDG-PET scan was positive in 16 patients and negative in 10. In 2 patients, the FDG-PET scan was positive while they were considered disease free on radiological evaluation. In 5 patients (20.8%), the previous therapeutic decision was changed. Thirteen patients had a pathological evaluation for 19 sites. One patient out of 13 had a false-positive FDG-PET scan, while 4 sites out of 6 were false-negative. The sensitivity was 75% (95% CI: 47.6–92.7) and the predictive positive value was 92.3% (95% CI: 64–99.8). With a median follow-up of 24 months, 3 patients developed new metastatic sites. Conclusion: Our data suggest that, when positive, an FDG-PET scan may modify the decision made; when negative, it should not modify decision-making especially for surgery, owing to its sensitivity.

Keywords:
Renal cell carcinoma, decision-making, Positron emission tomography scan
1.
Linehan WM, Bates SE, Yang JC: Cancer of the kidney and ureter; in DeVita VT Jr, Helmann S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 7. Philadelphia, Lippincott Williams and Wilkins, 2004, pp 1139–1167.
2.
Motzer RJ, Bander NH, Nanus DM: Renal cell carcinoma. N Engl J Med1996;335:865–875.
3.
Ravaud A, Debled M: Present achievements in the medical treatment of metastatic renal cell carcinoma. Crit Rev Oncol Hematol 1999;31:77–87.
4.
Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410–2411.
5.
Négrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T, Groupe Français d’Immunothérapie: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272–1278.
6.
Tanguay S, Swanson DA, Putnam JB Jr: Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J Urol 1996;156:1586–1589.
7.
Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS: Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;1:2261–2266.
8.
Sella A, Swanson DA, Roy JY, Putnam JB Jr, Amato RJ, Markowitz AB, Logothetis CJ: Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. J Urol 1993;149:19–21.
9.
Pogrebniak HW, Haas G, Linehan W, Rosenberg SA, Pass HI: Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 1992;54:33–38.
10.
Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scott AM: Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001;166:825–830.
11.
Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH: 131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 2002;23:229–236.
12.
Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, Czernin J: The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cancer. Clin Nephrol 2002;57:56–62.
13.
Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM: F-18 fluorodeoxyglucose of distant metastases from renal cell carcinoma. J Clin Oncol 2003;21:3995–4000.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.